Abstract: |
Biomarker testing is essential for the management of patients with metastatic non-small cell lung cancer (NSCLC) to identify specific actionablemutations and guide treatment decisions in EGFR-mutant disease and for the potential benefit of combining tyrosine kinase inhibitors with chemotherapy to improve progression-free survival. For instance, for patients with EGFR exon 20 insertions, the role of amivantamab, an EGFR-MET-bispecific antibody, is being explored in the first-line and second-line settings, in addition to the use of ROS1 inhibitors, such as repotrectinib, in the treatment of ROS1-rearranged NSCLC. For patients with BRAF V600E mutations, combining BRAF and MEK inhibitors, such as dabrafenib and trametinib or encorafenib and binimetinib, has demonstrated efficacy. The potential of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki in treating HER2-mutant NSCLC is under investigation. Finally, for patients with KRAS G12C mutations, sotorasib and adagrasib have been tested as second-line therapies, with ongoing trials evaluating their use in the first-line setting. |